Hidradenocarcinoma of scalp: a case report and review of literature


  • Sowjanya Gandla Department of Head and Neck Surgical Oncology, HCG, Bangalore
  • Satakshi Chatterjee Department of Head and Neck Surgical Oncology, HCG, Bangalore
  • Ashuthosh Patil Department of Head and Neck Surgical Oncology, HCG, Bangalore
  • Vishal Rao Department of Head and Neck Surgical Oncology, HCG, Bangalore




Hidradenocarcinoma, Adjuvant therapy


Hidradenocarcinoma of the scalp is a rare skin adnexal tumour accounting for less than 0.001% of all tumors. In this study, we describe a rare presentation of the hidradenocarcinoma of the scalp in a 64 years old man. Patient presented with a right side scalp lesion in the occipital area, for which biopsy was done which showed hidradenocarcinoma. Patient underwent wide local excision of the posterior scalp lesion and posterolateral neck dissection and the patient was advised to receive adjuvant chemotherapy and radiotherapy, but the patient refused to undergo adjuvant therapy. Six months postsurgery patient had local recurrence in the posterior margin resection area and lung metastasis, which could have been prevented by adjuvant therapy. Malignant hidradenocarcinoma is a rare aggressive malignant tumour. Patients with this tumour should undergo surgical excision followed by adjuvant therapy.


Santa Cruz DJ. Sweat gland carcinomas a comprehensive review. Semin Diagn Pathol. 1987;4(1):38-74.

Cohen M, Cassarino DS, Shih HB. Apocrine hidradenocarcinoma of the scalp. A classification Conundrum. Head And Neck Pathol. 2009;3:42-6.

Soni A, Bansal N, Kaushal V, Chauhan AK. Current management approach to hidradenocarcinoma: a comprehensive review of literature. E cancer Med Sci. 2015;9:517.

Keasbey LE, Hadley GG. Clear cell adeno-carcinoma; report of three cases with widespread metastases. Cancer. 1954;7:934-52.

Floros P, Mikhail P. A rare case of pectoral hidradenocarcinoma and brief review. Int J Surg. 2010;26:2.

Requena L, Kutzner H, Hurt MA, Santa Cruz DJ, Mehregan AH. Malignant tumors with apocrine and eccrine differentiation. In: LeBoit PE, Burg G, Weedon D, Sarasin A, editors. World Health Organization Classification of Tumours of Skin. Lyon: IARC press; 2006: 125–138.

Ohta M, Hiramoto M, Fujii M, Togo T. Nodular hidradenocarcinoma on the scalp of a young woman: case report and review of literature. Dermatol Surg. 2004;30:1265-8.

Lalya I, Hadadi K, Tazi EM, Lalya I, Bazine A, Andaloussy K, et al. Radiotherapy on hidradeno-carcinoma. North Am J Med Sci. 2011;3(1):343–5.

Ko CJ, Cochran AJ, Eng W, Binder SW. Hidradenocarcinoma: A histological and immune-histochemical study. J Cutan Pathol. 2006;33:726-30.

Nazarian RM, Kapur P, Rakheja D, Piris A, Duncan LM, Mihm MC, et al. Atypical and malignant hidradenomas: A histological and immune-histochemical study. Modern Pathol. 2009;22:600-10.

Kai SHU, Qungen XIAO, Buchele F, Zhang S. Diagnosis and treatment of clear cell hidradeno-carcinoma of scalp. J Huazhong Univ Sci Technol (Med Sci). 2012;32(6):931-6.

Park HJ, Kim YC, Cinn YM. Nodular hidradenocarcinoma with prominent squamous differentiation: case report and immune-histochemical study. J Curtin Pathol. 2000;27(8):423-7.

Tolkachjov SN, Hocker TL, Hochwalt PC, Camilleri MJ, Arpey CJ, Brewer JD, et al. Mohs Micrographic Surgery for the treatment of hidradenocarcinoma: The Mayo clinic experience from 1993 to 2013. Dermatol surg. 2015;41:226-31.

Harari PM, Shimm DS, Bangert JL, Cassady JR. The role of radiotherapy in the treatment of malignant sweat gland neoplasms. Cancer. 1990;65(8):1737–40.

Lerner A, Beckford A, Ugent S, Goldberg L, Jalisi S, Demierre MF. Complete response of metastatic malignant hidradenocarcinoma with capecitabine treatment. Arch Dermatol. 2011;147(8):998-9.






Case Reports